BeiGene
BGNE
#934
Rank
C$29.60 B
Marketcap
$266.09
Share price
-2.10%
Change (1 day)
-1.06%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

EPS for BeiGene (BGNE)

EPS in 2023 (TTM): -$22.50

According to BeiGene 's latest financial reports the company's current EPS (TTM) is -$23.40. In 2022 the company made an earnings per share (EPS) of -$27.24 a decrease over its 2021 EPS that were of -$21.39.

EPS history for BeiGene from 2015 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$22.50-17.38%
2022-$27.2427.35%
2021-$21.39-19.96%
2020-$26.7220.81%
2019-$22.1231.52%
2018-$16.82417.57%
2017-$3.25-37.16%
2016-$5.17158.95%
2015-$2.00

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$1.41-93.99%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.38-98.38%๐Ÿ‡บ๐Ÿ‡ธ USA